<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015235</url>
  </required_header>
  <id_info>
    <org_study_id>KAI-1678-002</org_study_id>
    <nct_id>NCT01015235</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trident Clinical Research Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KAI Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether KAI-1678 is effective in the treatment of
      postoperative pain following total hip or total knee replacement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of KAI-1678 on summed pain intensity difference over 4 hours (SPID 4).</measure>
    <time_frame>Post operative Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of KAI-1678 on total pain relief over 4 hours (TOTPAR 4)</measure>
    <time_frame>Post operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of KAI-1678 on pain intensity difference (PID) at 4 hours</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of KAI-1678 on total quality analgesia</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of KAI-1678 on time to meaningful pain relief</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: KAI-1678</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3: Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous infusion-once over 4 hours</description>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-1678</intervention_name>
    <description>Subcutaneous infusion-once over 4 hours</description>
    <arm_group_label>A2: KAI-1678</arm_group_label>
    <other_name>Active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>Active comparator, IV infusion, once</description>
    <arm_group_label>A3: Ketorolac</arm_group_label>
    <other_name>Ketorolac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist (ASA) classification 1, 2, or 3

          -  total hip or total knee replacement

          -  pain on postoperative Day 1 at least 40 mm on 0-100 mm visual analog scale (VAS)

        Exclusion Criteria:

          -  presence of contraindications to nonsteroidal anti-inflammatory (NSAID) treatment

          -  recent history of angina or myocardial infarction (MI)

          -  clinically significant abnormality on laboratory tests or electrocardiogram (ECG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Bell, MD</last_name>
    <role>Study Director</role>
    <affiliation>KAI Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketorolac / therapeutic use</keyword>
  <keyword>Analgesics. Non-narcotic / therapeutic use</keyword>
  <keyword>Arthroplasty, replacement hip</keyword>
  <keyword>Arthroplasty, replacement knee</keyword>
  <keyword>Pain measurement / drug effect</keyword>
  <keyword>Pain postoperative / drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

